S

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336

Watchlist Manager
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Watchlist
Price: 62.78 CNY -1.38% Market Closed
Market Cap: 38.7B CNY

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
S
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Net Income (Common)
ÂĄ704.6m
CAGR 3-Years
239%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ5B
CAGR 3-Years
20%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Net Income (Common)
-ÂĄ514.5m
CAGR 3-Years
22%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Net Income (Common)
ÂĄ2.4B
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Net Income (Common)
-ÂĄ266.8m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Glance View

Market Cap
38.7B CNY
Industry
Biotechnology

Sunshine Guojian Pharmaceutical Shanghai Co., Ltd. stands as a beacon of innovation in China’s bustling pharmaceutical landscape. Born from a vision to advance biotech research and development, the company has centered its efforts on the creation of monoclonal antibody drugs. These biologics are pivotal in treating complex diseases such as cancers and autoimmune disorders, positioning Sunshine Guojian at the forefront of biopharmaceutical excellence. The company's prowess is anchored in its robust R&D capabilities, with a specialized team of scientists and cutting-edge facilities driving the creation of therapeutics that meet global standards. By strategically focusing on biologics, the firm not only taps into a growing demand for advanced medical solutions but also strengthens its competitive edge in both domestic and international markets. The economic engine of Sunshine Guojian hums along with a well-oiled strategy of clinical development and commercialization. Partnering with healthcare professionals and institutions, the company ensures that its biologics are effectively integrated into treatment paradigms, thereby enhancing patient care and outcomes. Revenue streams flow through a mix of direct sales and strategic partnerships, both within China and abroad, where collaborative alliances help broaden market reach and drive scale. Moreover, its established networks enable the company to stay attuned to emerging medical needs and regulatory environments, adapting swiftly to maintain its leadership position. This adeptness in maneuvering the complex web of pharmaceutical offerings allows Sunshine Guojian not just to survive but to thrive, fueling sustainable growth and innovation in an ever-evolving health landscape.

Intrinsic Value
27.68 CNY
Overvaluation 56%
Intrinsic Value
Price
S

See Also

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Net Income (Common)?
Net Income (Common)
704.6m CNY

Based on the financial report for Dec 31, 2024, Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Net Income (Common) amounts to 704.6m CNY.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
25%

Over the last year, the Net Income (Common) growth was 139%. The average annual Net Income (Common) growth rates for Sunshine Guojian Pharmaceutical Shanghai Co Ltd have been 239% over the past three years , 25% over the past five years .

Back to Top